Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 05 Feb 2018 Status changed from recruiting to completed.
- 30 Dec 2016 Status changed from not yet recruiting to recruiting.
- 22 Sep 2016 New trial record